At the San Antonio Breast Cancer Symposium (SABCS), Px HealthCare (Px), the digital health company behind the clinically validated OWise cancer patient support app, announced today the first-of-its-kind Real World Evidence (RWE) study to be presented by the company.. This study is a nationwide RWE initiative that was developed by Px and AstraZeneca UK as part of a collaboration between the two companies. Patients prescribed trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) may take part in the study using the OWise app if they are prescribed with these medications in the UK.
This study is a nationwide RWE initiative that was developed by Px and AstraZeneca UK as part of a collaboration between the two companies. Patients prescribed trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) may take part in the study using the OWise app if they are prescribed with these medications in the UK.
A new treatment-specific version of OWise has been developed as part of this research to assist UK patients who have recently been prescribed one of the two treatments within their licensed indications. The study, called RELATE-2, evaluates the experience of patients who were treated with TDX-d or olaparib while using OWise's treatment-specific modules.
This study will be led by an international team of clinical researchers led by the Principal Investigator of the study, Dr.. As Sophie McGrath, a Consultant Medical Oncologist at the Royal Marsden Foundation Trust, noted, "RELATE-2 represents a new way to assess patient experiences in the real world, using a widely available, clinically-validated, cancer support application that is broadly available to patients. As a result, I look forward to gaining a detailed understanding of how patients experience the use of new treatment-specific support apps in specific patient groups across the country and across the entire country.
As a result, I look forward to gaining a detailed understanding of how patients experience the use of new treatment-specific support apps in specific patient groups across the country and across the entire country.
As Dr. Anne Bruinvels, Founder and CEO of Px, pointed out, "The RELATE-2 study is a novel approach to conducting patient-centered, Real World Evidence research. The OWise app for breast cancer patients, which is freely available on the internet, allows patients who are taking TDX-D or olaparib to get personalized support. Also, patients can consent directly to clinical research through the app. In addition to empowering patients, OWise is designed to deliver insights that can help reshape patient care."
You can access the RELATE-2 poster presented by Principal Investigator Dr. Sophie McGrath at the 2023 San Antonio Breast Cancer Symposium by clicking on the following link: https://pxhealthcare.com/cms/wp-content/uploads/RELATE-2-SABCS-POSTER.pdf.
If you would like to know more about OWise, please visit their website at https://owise.uk/
Notes can be accessed here: https://pxhealthcare.com/relate-2-notes
PRNewswire - Sales - SOURCE PRNewswire
If you'd like to receive PRN's top stories and curated news delivered to your inbox on a weekly basis, sign up now!

Source prnewswire